Biotricity, Inc. (BTCY)
| Market Cap | 2.12M -83.7% |
| Revenue (ttm) | 16.00M +16.0% |
| Net Income | -3.13M |
| EPS | -0.11 |
| Shares Out | 20.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,964 |
| Open | 0.1053 |
| Previous Close | 0.1100 |
| Day's Range | 0.1050 - 0.1100 |
| 52-Week Range | 0.0879 - 0.7536 |
| Beta | 1.15 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 26, 2026 |
About Biotricity
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It also offers Bioflux and Biocore Pro, an integrated ECG device and software that utilizes wet electrodes for cardiac outpatient monitoring (COM) market; Biocore, a Holter and Extended Holter monitors for cardiac diagnostics; Biocare whi... [Read more]
Financial Performance
In fiscal year 2026, Biotricity's revenue was $16.00 million, an increase of 16.01% compared to the previous year's $13.79 million. Losses were -$3.13 million, -73.80% less than in 2025.
Financial StatementsNews
Biotricity Annual report: Q4 2026
Biotricity has published its Q4 2026 annual report on July 14, 2026.
Biotricity Transcript: 16th Annual LD Micro Invitational Conference
A vertically integrated cardiac monitoring company has achieved profitability, high margins, and strong customer retention by offering a cellular-enabled, SaaS-based device that simplifies workflow and increases physician revenue. Expansion into disease management and implantable monitoring, along with strategic partnerships and a growing commercial team, are expected to drive future growth.
Biotricity, Inc to Present at the LD Micro Invitational XVI
Redwood City, California--(Newsfile Corp. - May 12, 2026) - Biotricity, Inc (OTCQB: BTCY) announced today that it will be participating in the 16th Annual LD Micro Invitational at the Luxe Sunset Boul...
Biotricity Earnings Call Transcript: Q3 2026
Revenue grew 10.2% year-over-year to $4M, with gross margin rising to 81.5% and positive EBITDA for the third consecutive quarter. The company expects continued revenue growth and aims for net income profitability in 2026, driven by strong adoption of its cardiac monitoring solutions.
Biotricity Earnings release: Q3 2026
Biotricity released its Q3 2026 earnings on February 11, 2026, summarizing the period's financial results.
Biotricity Quarterly report: Q3 2026
Biotricity has published its Q3 2026 quarterly earnings report on February 11, 2026.
Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA
REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to transforming chronic...
Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th
Company continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), ...
Biotricity Registration statement: Registration Filing
Biotricity filed a registration statement on December 19, 2025, providing details about a securities offering with the SEC.
Biotricity Earnings Call Transcript: Q2 2026
Revenue grew 19% year-over-year to $3.9M, with gross margin rising to 81.9% and EBITDA positive for the second consecutive quarter. Strategic partnerships, product innovation, and commercial expansion are expected to drive continued growth and profitability.
Biotricity Earnings release: Q2 2026
Biotricity released its Q2 2026 earnings on November 14, 2025, summarizing the period's financial results.
Biotricity Quarterly report: Q2 2026
Biotricity has published its Q2 2026 quarterly earnings report on November 14, 2025.
Biotricity Strengthens Path to Scalable Profitability with Sustained Margins & Operational Efficiency in Second Quarter Fiscal 2026
REDWOOD CITY, CA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to redefining the lands...
Biotricity to Host Fiscal 2026 Second Quarter Financial Results and Business Update Call on November 14th
REDWOOD CITY, CA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to redefining the lands...
Biotricity, Health-E Commerce collaborate to expand remote cardiac monitoring
Health-E Commerce announced a new collaboration with Biotricity (BTCY). Through this arrangement, Biotricity’s continuous 24/7 wearable cardiac monitoring solution, Bioheart, will now be available to ...
Health-E Commerce® and Biotricity® Collaborate to Expand Remote Cardiac Monitoring with Bioheart® for Flexible Spending Account (FSA) and Health Savings Account (HSA) Users
New telehealth offering empowers consumers to use pre-tax healthcare funds at FSA Store® and HSA Store® to make heart health a part of everyday life with at-homemonitoring DALLAS and REDWOOD CITY, Cal...
Biotricity, B-Secur expand cardiac monitoring platform
Biotricity (BTCY) and B-Secur are transforming the consumer wearables market with an enhancement to their joint cardiac monitoring platform. The device-neutral platform, which launched in early 2025 f...
Biotricity and B-Secur Target the Consumer Wearables Market with Expansion of Next-Gen Cardiac Monitoring Platform
REDWOOD CITY, Calif./BELFAST, Northern Ireland, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative medical technology company specializing in remote cardiac monitoring solu...
Biotricity Earnings Call Transcript: Q1 2026
Revenue grew 21% year-over-year to $3.9M, with gross margin rising to 80.5%. Achieved first-ever positive EBITDA of $333K and operating profit, while net loss narrowed significantly. Strategic partnerships and regulatory approvals support continued growth.
Biotricity Earnings release: Q1 2026
Biotricity released its Q1 2026 earnings on August 14, 2025, summarizing the period's financial results.
Biotricity Quarterly report: Q1 2026
Biotricity has published its Q1 2026 quarterly earnings report on August 14, 2025.
Biotricity reports Q1 EPS (3c) vs (49c) last year
Reports Q1 revenue $3.9M vs. $3.2M in Q4. Dr. Waqaas Al-Siddiq, Biotricity (BTCY) Founder & CEO, said, “We’re proud to deliver another quarter of strong performance and a shift to…
Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins
REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to redefining the lands...
Biotricity to Host Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14th
Company to announce continued Revenue Growth, Improvements in Margins, Operational Efficiency, and a shift to positive EBITDA
Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach
REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chronic di...